Adam L. Boxer, MD, PhD is the Endowed Professor in Memory and Aging in the Department of Neurology at the University of California, San Francisco (UCSF). He received his MD and PhD from the New York University Medical Center Medical Scientist Training Program, completed a Neurology Residency at Stanford and a Neurobehavior Fellowship at UCSF. Dr. Boxer directs the Neurosciences Clinical Research Unit and the Alzheimer’s Disease and Frontotemporal Degeneration (FTD) Clinical Trials Program at the UCSF Memory and Aging Center. Dr. Boxer’s research is focused on developing new treatments and biomarkers for neurodegenerative diseases, particularly those involving tau and TDP-43. He leads the Four Repeat Tauopathy Neuroimaging Initiative (4RTNI), a NIH-funded, multicenter, longitudinal tau PET and biomarker study focused on PSP and CBD. He is co-Principal Investigator of the ARTFL/LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) project, a new 18 site research network focused on preparing for FTLD clinical trials. He has been the PI for a variety of multicenter, randomized, placebo controlled clinical trials in neurodegenerative diseases, including memantine for FTLD, davunetide for PSP, TPI-287 for primary and secondary tauopathies, a Phase 1b trial of gosuranemab for PSP, and salsalate for Alzheimer’s Disease and PSP. He co-chairs the FTLD Treatment Study Group (FTSG) and the PSP Research Roundtable, academic-industry collaborative groups working to speed the development of new therapies for FTLD, CBD and PSP.
COMTEC SPAIN
Bailen, 95 – 97
pral.1.a – 08009
Barcelona, Spain
Tel: +34-932081145
Fax: +34-934579291
spain-office@comtecmed.com
COMTEC CHINA
Suite 405, Universal Center Building
175 Xiang Yang Road South
Shanghai 200031, China
Tel: +86-21-54660460
Fax: +86-21-54660450
china-office@comtecmed.com
COMTEC USA
415 South Street
POB #3627
Waltham, MA 02453-2700
Tel: +1-914-312-5407
Fax: 972-3-566-6177
usa-office@comtecint.com